Treatment-related adverse events (N=16 patients)
| Any grade | Grade 3–4 | |
| Any | 12 (75.0%) | 4 (25.0%) |
| Serious | 3 (18.8%) | 2 (12.5%) |
| Led to discontinuation | 2 (12.5%) | 2 (12.5%) |
| Lead to death | 0 (0.0%) | 0 (0.0%) |
| >5% of Patients | ||
| Alanine aminotransferase increased | 3 (18.8%) | 1 (6.3%) |
| Anemia | 3 (18.8%) | 1 (6.3%) |
| Aspartate aminotransferase increased | 3 (18.8%) | 1 (6.3%) |
| Diarrhea | 3 (18.8%) | 1 (6.3%) |
| Fatigue | 3 (18.8%) | 0 (0%) |
| Hypothyroidism | 3 (18.8%) | 0 (0%) |
| Pneumonitis | 3 (18.8%) | 0 (0%) |
| Pruritus | 3 (18.8%) | 0 (0%) |
| Rash maculo-papular | 3 (18.8%) | 0 (0%) |
| Alkaline phosphatase increased | 2 (12.5%) | 1 (6.3%) |
| Hypokalemia | 2 (12.5%) | 1 (6.3%) |
| Neutrophil count decreased | 2 (12.5%) | 1 (6.3%) |
| Fever | 2 (12.5%) | 0 (0%) |
| Hyponatremia | 2 (12.5%) | 0 (0%) |
| Infusion-related reaction | 2 (12.5%) | 0 (0%) |
| Insomnia | 2 (12.5%) | 0 (0%) |
| Lipase increased | 2 (12.5%) | 0 (0%) |
| Lymphocyte count decreased | 2 (12.5%) | 0 (0%) |
| Nausea | 2 (12.5%) | 0 (0%) |
| Vomiting | 2 (12.5%) | 0 (0%) |
| Hepatobiliary disorders—other, specify: drug-induced hepatitis | 1 (6.3%) | 1 (6.3%) |
| Infections and infestations—other, specify: drug-induced hepatitis | 1 (6.3%) | 1 (6.3%) |
| Muscle weakness lower limb | 1 (6.3%) | 1 (6.3%) |
| Pneumothorax | 1 (6.3%) | 1 (6.3%) |
| Anorexia | 1 (6.3%) | 0 (0%) |
| Arthralgia | 1 (6.3%) | 0 (0%) |
| Back pain | 1 (6.3%) | 0 (0%) |
| Bone pain | 1 (6.3%) | 0 (0%) |
| Dry mouth | 1 (6.3%) | 0 (0%) |
| Dry skin | 1 (6.3%) | 0 (0%) |
| Dysgeusia | 1 (6.3%) | 0 (0%) |
| Dyspnea | 1 (6.3%) | 0 (0%) |
| Endocrine disorders—other, specify: ACTH increased | 1 (6.3%) | 0 (0%) |
| Gastrointestinal pain | 1 (6.3%) | 0 (0%) |
| Hepatobiliary disorders—other, specify: immune-mediated hepatitis | 1 (6.3%) | 0 (0%) |
| Hyperglycemia | 1 (6.3%) | 0 (0%) |
| Hyperthyroidism | 1 (6.3%) | 0 (0%) |
| Hypocalcemia | 1 (6.3%) | 0 (0%) |
| Neuralgia | 1 (6.3%) | 0 (0%) |
| Pain in extremity | 1 (6.3%) | 0 (0%) |
| Platelet count decreased | 1 (6.3%) | 0 (0%) |
| Pleural effusion | 1 (6.3%) | 0 (0%) |
| Rash acneiform | 1 (6.3%) | 0 (0%) |
| Serum amylase increased | 1 (6.3%) | 0 (0%) |
| Weight loss | 1 (6.3%) | 0 (0%) |
| Immune-mediated | 11 (68.8%) | 2 (12.5%) |
| Alanine aminotransferase increased | 3 (18.8%) | 1 (6.3%) |
| Aspartate aminotransferase increased | 3 (18.8%) | 1 (6.3%) |
| Diarrhea | 3 (18.8%) | 1 (6.3%) |
| Hypothyroidism | 3 (18.8%) | 0 (0%) |
| Pneumonitis | 3 (18.8%) | 0 (0%) |
| Pruritus | 3 (18.8%) | 0 (0%) |
| Rash maculo papular | 3 (18.8%) | 0 (0%) |
| Infusion-related reaction | 2 (12.5%) | 0 (0%) |
| Lipase increased | 2 (12.5%) | 0 (0%) |
| Arthralgia | 1 (6.3%) | 0 (0%) |
| Hyperthyroidism | 1 (6.3%) | 0 (0%) |
| Serum amylase increased | 1 (6.3%) | 0 (0%) |